GB202008248D0 - Hybrid Antibody - Google Patents

Hybrid Antibody

Info

Publication number
GB202008248D0
GB202008248D0 GBGB2008248.3A GB202008248A GB202008248D0 GB 202008248 D0 GB202008248 D0 GB 202008248D0 GB 202008248 A GB202008248 A GB 202008248A GB 202008248 D0 GB202008248 D0 GB 202008248D0
Authority
GB
United Kingdom
Prior art keywords
hybrid antibody
antibody
hybrid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2008248.3A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epsilogen Ltd
Original Assignee
Epsilogen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epsilogen Ltd filed Critical Epsilogen Ltd
Priority to GBGB2008248.3A priority Critical patent/GB202008248D0/en
Publication of GB202008248D0 publication Critical patent/GB202008248D0/en
Priority to CN202080082725.3A priority patent/CN115175736A/en
Priority to EP20789871.9A priority patent/EP4041397A1/en
Priority to CN202080083349.XA priority patent/CN114761087A/en
Priority to PCT/EP2020/077609 priority patent/WO2021064153A1/en
Priority to CA3152084A priority patent/CA3152084A1/en
Priority to PCT/EP2020/077608 priority patent/WO2021064152A1/en
Priority to US17/764,854 priority patent/US20220380482A1/en
Priority to JP2022520761A priority patent/JP2022550976A/en
Priority to BR112022006364A priority patent/BR112022006364A2/en
Priority to JP2022520650A priority patent/JP2022552805A/en
Priority to US17/764,850 priority patent/US20230059181A1/en
Priority to AU2020360962A priority patent/AU2020360962A1/en
Priority to EP20789872.7A priority patent/EP4041398A1/en
Priority to MX2022004073A priority patent/MX2022004073A/en
Priority to KR1020227009817A priority patent/KR20220070215A/en
Priority to AU2020358898A priority patent/AU2020358898A1/en
Priority to CA3152097A priority patent/CA3152097A1/en
Ceased legal-status Critical Current

Links

GBGB2008248.3A 2019-10-01 2020-06-02 Hybrid Antibody Ceased GB202008248D0 (en)

Priority Applications (18)

Application Number Priority Date Filing Date Title
GBGB2008248.3A GB202008248D0 (en) 2020-06-02 2020-06-02 Hybrid Antibody
CA3152097A CA3152097A1 (en) 2019-10-01 2020-10-01 Hybrid antibody
JP2022520761A JP2022550976A (en) 2019-10-01 2020-10-01 hybrid antibody
JP2022520650A JP2022552805A (en) 2019-10-01 2020-10-01 hybrid antibody
CN202080083349.XA CN114761087A (en) 2019-10-01 2020-10-01 Hybrid antibodies
PCT/EP2020/077609 WO2021064153A1 (en) 2019-10-01 2020-10-01 Hybrid antibody
CA3152084A CA3152084A1 (en) 2019-10-01 2020-10-01 Hybrid antibody
PCT/EP2020/077608 WO2021064152A1 (en) 2019-10-01 2020-10-01 Hybrid antibody
US17/764,854 US20220380482A1 (en) 2019-10-01 2020-10-01 IgE Antibody with FcRn binding
CN202080082725.3A CN115175736A (en) 2019-10-01 2020-10-01 Hybrid antibodies
BR112022006364A BR112022006364A2 (en) 2019-10-01 2020-10-01 HYBRID ANTIBODY
EP20789871.9A EP4041397A1 (en) 2019-10-01 2020-10-01 Hybrid antibody
US17/764,850 US20230059181A1 (en) 2019-10-01 2020-10-01 IgE Antibody with Fcgamma Receptor binding
AU2020360962A AU2020360962A1 (en) 2019-10-01 2020-10-01 Hybrid antibody
EP20789872.7A EP4041398A1 (en) 2019-10-01 2020-10-01 Hybrid antibody
MX2022004073A MX2022004073A (en) 2019-10-01 2020-10-01 Hybrid antibody.
KR1020227009817A KR20220070215A (en) 2019-10-01 2020-10-01 hybrid antibody
AU2020358898A AU2020358898A1 (en) 2019-10-01 2020-10-01 Hybrid antibody

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2008248.3A GB202008248D0 (en) 2020-06-02 2020-06-02 Hybrid Antibody

Publications (1)

Publication Number Publication Date
GB202008248D0 true GB202008248D0 (en) 2020-07-15

Family

ID=71526420

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2008248.3A Ceased GB202008248D0 (en) 2019-10-01 2020-06-02 Hybrid Antibody

Country Status (1)

Country Link
GB (1) GB202008248D0 (en)

Similar Documents

Publication Publication Date Title
SI3872091T1 (en) Antibodies against sars-cov-2
IL308741A (en) Anti-sirp-alpha antibodies
IL311043A (en) Anti-il-11rα antibodies
IL300142A (en) ANTI-IL13Ralpha2 ANTIBODIES
GB202105110D0 (en) Anti-CD73 antibodies
GB202015115D0 (en) ZIP12 Antibody
GB202014851D0 (en) SARS-COV-2 antibodies
GB202008248D0 (en) Hybrid Antibody
GB201917059D0 (en) Hybrid antibody
GB201914165D0 (en) Hybrid antibody
IL304741A (en) Hybrid aav-anellovectors
EP4342989A4 (en) Anti-norovirus antibody
GB202106027D0 (en) Antibody
GB202105933D0 (en) Anti-IL1rap antibody
GB202014969D0 (en) ZIP12 antibody
IL310245A (en) Anti-hla-g antibodies
GB202208773D0 (en) Anti-SARS2-S antibodies
IL308782A (en) Antibodies
IL308100A (en) Antibodies
IL307175A (en) Il-38-specific antibodies
GB202116709D0 (en) Antibodies
GB202115824D0 (en) Antibodies
GB202112297D0 (en) Antibodies
IL299767A (en) Anti-αlpha-4-βeta-7 antibodies
GB202107517D0 (en) Antibodies

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)